Kolařík L., Horáková D., Vlčková J., Matoušková I.: Epidemiological situation of Hodgkin's lymphoma with predictive modeling of global incidence and mortality in 2040.
{"title":"Kolařík L., Horáková D., Vlčková J., Matoušková I.: Epidemiological situation of Hodgkin's lymphoma with predictive modeling of global incidence and mortality in 2040.","authors":"L Kolařík, D Horáková, J Vlčková, I Matoušková","doi":"10.61568/emi/11-6390/20241024/138873","DOIUrl":null,"url":null,"abstract":"<p><strong>The aim of the work: </strong>The aim of our work was to describe the current epidemiological situation of Hodgkin's lymphoma (HL) with a possible global prediction for the year 2040.</p><p><strong>Methods: </strong>We obtained data on incidence and mortality of HL using the GLOBOCAN database. The rating was done specifically for men and women and together, with an age range of 0-85+ years. For the possibility of international comparison, the data are evaluated in the format of age standardized incidence/mortality (Age Standardized Rate - ASR) related to the world population - ASR (W).</p><p><strong>Results: </strong>In the period 2000-2010, the incidence of the lowest values in the male population in Sweden reached 1.90 ASR (W), the highest values reached 3.45 ASR (W) in Italy. In the female population, the lowest incidence was reported in Malta 1.63 ASR (W), the highest in Italy 3.34 ASR (W). The lowest mortality in the male population was reported in Norway at 0.21 ASR (W), the highest value was in Bulgaria at 0.85 ASR (W). In the female population, the lowest mortality value was reported in Iceland 0.09 ASR (W), the highest value in Poland 0.43 ASR (W). In 2040, 19,788 new cases of HL will be reported in Europe (104,317 in the world), the number of deaths will be 4,633 deaths in 2040 (34,237 in the world).</p><p><strong>Conclusion: </strong>HL in Europe shows a continuously increasing trend of incidence in the prescription period 2000-2010, but continuously decreasing trend in mortality. In 2020, within Europe, the lowest incidence value was reported in Central and Eastern Europe, the highest incidence value was reported in Southern Europe. In the same year, the lowest value of mortality was reported in Western Europe, the highest value was reported in Central and Eastern Europe. Modeling the epidemiology of the disease for the world for the year 2040 is important, as the disease will continue to be more common in the male population in the future.</p>","PeriodicalId":54374,"journal":{"name":"Epidemiologie Mikrobiologie Imunologie","volume":"73 4","pages":"181-191"},"PeriodicalIF":0.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologie Mikrobiologie Imunologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61568/emi/11-6390/20241024/138873","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of the work: The aim of our work was to describe the current epidemiological situation of Hodgkin's lymphoma (HL) with a possible global prediction for the year 2040.
Methods: We obtained data on incidence and mortality of HL using the GLOBOCAN database. The rating was done specifically for men and women and together, with an age range of 0-85+ years. For the possibility of international comparison, the data are evaluated in the format of age standardized incidence/mortality (Age Standardized Rate - ASR) related to the world population - ASR (W).
Results: In the period 2000-2010, the incidence of the lowest values in the male population in Sweden reached 1.90 ASR (W), the highest values reached 3.45 ASR (W) in Italy. In the female population, the lowest incidence was reported in Malta 1.63 ASR (W), the highest in Italy 3.34 ASR (W). The lowest mortality in the male population was reported in Norway at 0.21 ASR (W), the highest value was in Bulgaria at 0.85 ASR (W). In the female population, the lowest mortality value was reported in Iceland 0.09 ASR (W), the highest value in Poland 0.43 ASR (W). In 2040, 19,788 new cases of HL will be reported in Europe (104,317 in the world), the number of deaths will be 4,633 deaths in 2040 (34,237 in the world).
Conclusion: HL in Europe shows a continuously increasing trend of incidence in the prescription period 2000-2010, but continuously decreasing trend in mortality. In 2020, within Europe, the lowest incidence value was reported in Central and Eastern Europe, the highest incidence value was reported in Southern Europe. In the same year, the lowest value of mortality was reported in Western Europe, the highest value was reported in Central and Eastern Europe. Modeling the epidemiology of the disease for the world for the year 2040 is important, as the disease will continue to be more common in the male population in the future.
Kolařík L., Horáková D., vl kov J., Matoušková I.: 2040年霍奇金淋巴瘤全球发病率和死亡率预测模型的流行病学情况。
工作目的:我们工作的目的是描述霍奇金淋巴瘤(HL)的流行病学现状,并对2040年进行可能的全球预测。方法:我们使用GLOBOCAN数据库获取HL的发病率和死亡率数据。该评级是专门针对男性和女性进行的,年龄范围为0-85岁以上。为便于国际比较,采用年龄标准化发病率/死亡率(age standarstandarrate - ASR)与世界人口- ASR (W)相关的格式对数据进行评价。结果:2000-2010年期间,瑞典男性人口发病率最低为1.90 ASR (W),意大利最高为3.45 ASR (W)。女性,发病率最低的是在马耳他1.63 ASR (W)报道,在意大利最高3.34 ASR (W)。男性人口死亡率最低的报道在挪威0.21 ASR (W),最高价值是在保加利亚在0.85 ASR (W)。女性人口死亡率最低的价值被报道在冰岛0.09 ASR (W),最高的价值在波兰0.43 ASR (W)。2040年,霍奇金淋巴瘤19788例新病例将在欧洲报道世界上(104317),到2040年,死亡人数将达到4 633人(世界为34 237人)。结论:欧洲HL处方期发病率呈持续上升趋势,死亡率呈持续下降趋势。2020年,在欧洲范围内,中欧和东欧报告的发病率最低,南欧报告的发病率最高。同年,西欧报告的死亡率最低,中欧和东欧报告的死亡率最高。为2040年的世界建立该病的流行病学模型是很重要的,因为这种疾病未来将继续在男性人口中更为常见。
期刊介绍:
The journal publishes original papers, information from practice, reviews on epidemiological and microbiological subjects. Sufficient space is devoted to diagnostic methods from medical microbiology, parasitology, immunology, and to general aspects and discussions pertaining to preventive medicine. It also brings translations and book reviews useful for medical doctors and research workers and professionals in public health.